AstraZeneca PLC (AZN) Meet the Management at ESMO 2024 Conference (Transcript)
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
Sanofi, AstraZeneca Win US Approval for New RSV Vaccine Manufacturing Line
J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)
Multiple pharmaceutical companies are betting on cancer targeted radiotherapy technology, with an investment of about 10 billion US dollars.
Healthcare Glogou September 16th | Several major pharmaceutical companies have already bet on cancer targeted radiotherapy technology - the upcoming therapy that directly delivers radioactive drugs to tumors - which will be the next major breakthrough in cancer treatment. Bristol-Myers Squibb, Astrazeneca, Eli Lilly and Co, and other pharmaceutical companies have spent about $10 billion on acquisitions or collaborations with radioactive drug manufacturers. They are snapping up emerging players in the industry to gain access to technology that can treat multiple types of cancer. Guggenheim Securities
Sanofi Shipping Beyfortus in US Ahead of Respiratory Syncytial Virus Disease Season